Gufic Biosciences Limited
All news and filings related to Gufic Biosciences Limited.
View all news & filings- Medium impact
Gufic Biosciences Limited's 42nd AGM: All resolutions passed, including dividend and director re-appointments.
Gufic Biosciences Limited's 42nd AGM on September 4, 2026, passed all resolutions. Key approvals include the FY26 financial statements, a 10% final dividend (Re. 0.10/share), director re-appointments for Mr. Pranav J. Choksi and Mr. Pankaj J. Gandhi, and auditor remuneration.
Read the summary - Low impact
Gufic Biosciences Holds 42nd AGM on Sept 4, 2026, Discusses Financials and Dividend
Gufic Biosciences held its 42nd AGM on September 4, 2026, to adopt FY26 financial statements and approve a 10% final dividend. Key agenda items included director re-appointments and auditor remuneration ratification. Voting results will be published within two working days.
Read the summary - Low impact
Gufic Biosciences Promotes Ami Shah and Pinak Padhya in Senior Management
Gufic Biosciences promoted Ms. Ami Shah to Head-Legal and Mr. Pinak Padhya to President – Sales & Marketing, effective September 02, 2026. Both promotions are a result of their extensive experience and contributions to the company.
Read the summary - Medium impact
Gufic Biosciences Q1 FY27 Earnings Call Transcript Released
Gufic Biosciences Q1 FY27 revenue reached ₹260.8 crores, up from ₹226.9 crores year-on-year. EBITDA rose to ₹47.2 crores with an 18.09% margin. The company is expanding manufacturing capabilities at its Indore facility and launching new products. International expansion and EU certification are key strategic focuses for future growth.
Read the summary - Low impact
Gufic Biosciences Announces Special Window for Share Re-lodgement and Dematerialisation
Gufic Biosciences opens a special window for physical share re-lodgement and dematerialisation from February 05, 2026, to February 04, 2027. This applies to securities sold/purchased before April 01, 2019, including previously rejected transfers. Transferred shares will be in demat mode with a one-year lock-in.
Read the summary - Low impact
Gufic Biosciences Releases Audio Recording of Earnings Conference Call
Gufic Biosciences Limited has released the audio recording of its earnings conference call held on August 17, 2026. The transcript will be provided later. The recording is accessible via the company's website.
Read the summary - Low impact
Gufic Biosciences Announces Q1 FY27 Unaudited Financial Results
Gufic Biosciences Limited reported its unaudited financial results for the quarter ended June 30, 2026. The results were approved by the Board on August 14, 2026, and published in newspapers on August 15, 2026.
Read the summary - Medium impact
Gufic Biosciences Q1 FY27: Investor Presentation Filed, Focus on Indore Facility & Global Expansion
Gufic Biosciences filed its Q1 FY27 investor presentation. The Indore facility is nearing completion for advanced injectables. The company is expanding its hospital injectable, women's health, and aesthetics platforms, alongside a strategic shift in its international business model towards IP ownership. Q1 FY27 revenue was ₹260.8 crore, with PAT at ₹22.0 crore.
Read the summary - Medium impact
Gufic Biosciences to Incorporate Subsidiary in Philippines, Invests Up to $250,000
Gufic Biosciences will incorporate a subsidiary in the Philippines, Gufic Philippines Inc., to market and distribute its pharmaceutical products. The company will invest up to USD 250,000 (approx. ₹2.08 crore) via cash subscription, holding 99.99% equity. This move aims to expand its business presence and IP management in the region. Incorporation is expected within 12 months.
Read the summary - Medium impact
Gufic Biosciences Approves Q1 FY27 Results and Philippines Subsidiary
Gufic Biosciences reported its Q1 FY27 results on August 14, 2026. The company also approved establishing a subsidiary in the Philippines with an investment of up to USD 250,000 (approx. ₹2.08 crore) to expand its market presence and manage intellectual property.
Read the summary - Low impact
Gufic Biosciences Announces 42nd AGM on Sep 4, 2026, via VC/OAVM
Gufic Biosciences Limited will hold its 42nd AGM on September 4, 2026, via video conference. The company has dispatched the AGM notice and annual report electronically. Remote e-voting will be available from September 1 to September 3, 2026. The Register of Members will close from August 29 to September 4, 2026.
Read the summary - Medium impact
Gufic Biosciences: AGM on Sept 4, Book Closure Aug 29-Sept 4 for Dividend
Gufic Biosciences will hold its 42nd AGM on September 4, 2026, via VC/OAVM. The company proposes a final dividend of 10% (₹0.10 per share) for FY2026, subject to approval. Book closure for AGM and dividend payment is from August 29 to September 4, 2026, with a record date of August 28, 2026.
Read the summary - Medium impact
Gufic Biosciences Announces 42nd AGM on Sept 4, 2026, Declares 10% Dividend
Gufic Biosciences will hold its 42nd AGM on September 4, 2026, to approve the FY26 financial statements and a 10% final dividend (₹0.10/share). The register of members will close from August 29 to September 4, 2026. The company also plans to re-appoint Pankaj J. Gandhi as Whole Time Director for five years.
Read the summary - Low impact
Gufic Biosciences Announces 42nd AGM on Sep 4, 2026, via VC/OAVM
Gufic Biosciences will hold its 42nd AGM on September 4, 2026, via VC/OAVM. A final dividend of ₹0.10 per share has been recommended, payable by October 3, 2026, to members on record as of August 28, 2026. Annual reports and AGM notices will be sent electronically.
Read the summary - Low impact
Gufic Biosciences Re-appoints Pankaj Gandhi as Whole Time Director for 5 Years
Gufic Biosciences Limited's Board has approved the re-appointment of Mr. Pankaj Jayakumar Gandhi as Whole Time Director for a five-year term, from September 7, 2026, to September 6, 2031. This is subject to shareholder approval at the 42nd Annual General Meeting.
Read the summary - Low impact
Gufic Biosciences reappoints Pankaj Gandhi as Whole Time Director for 5 years
Gufic Biosciences Limited's board approved the re-appointment of Mr. Pankaj Jayakumar Gandhi as Whole Time Director for a 5-year term from September 7, 2026, to September 6, 2031. This reappointment requires shareholder approval at the upcoming 42nd AGM.
Read the summary - Low impact
Gufic Biosciences Files SEBI Compliance Certificate for Q1 FY27
Gufic Biosciences Limited submitted a compliance certificate for the quarter ended June 30, 2026. The certificate, received from RTA MUFG Intime India, confirms the proper processing and cancellation of dematerialized securities as per SEBI regulations.
Read the summary - Low impact
Gufic Biosciences: Notice to Equity Shareholders for IEPF Share Transfer
Gufic Biosciences is transferring shares with unclaimed dividends from FY 2018-19 to the IEPF Authority by October 30, 2026. Shareholders must claim their dividends by this date. The company has notified relevant shareholders and published details on its website.
Read the summary - Low impact
Gufic Biosciences Announces Special Window for Share Transfer and Dematerialization
Gufic Biosciences opens a special window for share transfer and dematerialisation of physical securities from Feb 05, 2026, to Feb 04, 2027. This facility is for transactions before April 01, 2019, including previously rejected transfers. Transferred securities will be in demat mode with a one-year lock-in.
Read the summary - Low impact
Gufic Biosciences Clarifies Share Subscription in Saraswat Bank
Gufic Biosciences clarifies its share subscription in Saraswat Bank is for share-linkage requirements, not an investment. The company has existing credit facilities of ₹230 crore with the bank and is increasing its share linkage within RBI-prescribed limits, which will not alter control or governance.
Read the summary - Low impact
Gufic Biosciences Clarifies Saraswat Bank Share Subscription
Gufic Biosciences clarifies its share subscription in Saraswat Co-operative Bank is for share-linkage requirements, not an ownership stake. The company has credit facilities of ₹230 crore with Saraswat Bank and is subscribing to additional shares within RBI-prescribed limits, without impacting control or governance.
Read the summary - Low impact
Gufic Biosciences: Audio Recording of Earnings Conference Call Available
Gufic Biosciences Limited has made the audio recording of its earnings conference call held on June 01, 2026, available on its website. A written transcript will be provided later.
Read the summary - Low impact
Gufic Biosciences Announces Audited Financial Results for FY26
Gufic Biosciences Limited announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results on May 29, 2026. Full details are available on the company and stock exchange websites.
Read the summary - Low impact
Gufic Biosciences Appoints M/s. Poddar & Co. as Cost Auditors, Mrs. Saroj Kirdolia as Internal Auditor
Gufic Biosciences Limited's Board of Directors re-appointed M/s. Poddar & Co. as Cost Auditors for FY 2026-27. Mrs. Saroj R. Kirdolia was appointed as Internal Auditor for the same financial year. Both appointments were approved on May 29, 2026.
Read the summary - Medium impact
Gufic Biosciences Invests ₹5.75 Cr in Saraswat Bank
Gufic Biosciences will invest ₹5.75 Crore in Saraswat Co-operative Bank by subscribing to 57,50,800 equity shares. The acquisition aims to strengthen banking relations and is part of the company's treasury strategy. The investment is expected to be completed within four months.
Read the summary - Medium impact
Gufic Biosciences Recommends 10% Final Dividend for FY26
Gufic Biosciences Limited's Board has recommended a final dividend of 10% (Re. 0.10 per share) for FY26. This is subject to shareholder approval at the upcoming AGM. The dividend will be paid as per statutory timelines if approved.
Read the summary - Medium impact
Gufic Biosciences FY26 Consolidated Revenue at ₹94,047 Crore; Recommends 10% Dividend
Gufic Biosciences reported audited consolidated revenue of ₹94,047.54 crore and a net profit of ₹6,314.87 lakh for FY26. The company recommended a final dividend of ₹0.10 per share (10%) for FY26, pending shareholder approval at the AGM.
Read the summary - Medium impact
Gufic Biosciences Approves FY26 Final Dividend, FY26 Results, and Appoints Auditors
Gufic Biosciences reported its audited financial results for FY26. The company recommended a final dividend of 10% (Re. 0.10 per share) for FY26. M/s. Poddar & Co. was re-appointed as Cost Auditor, and Mrs. Saroj R. Kirdolia appointed as Internal Auditor for FY27. An investment of ₹5.75 crore in Saraswat Co-operative Bank was also approved.
Read the summary - Low impact
Gufic Biosciences Schedules Earnings Conference Call for June 1, 2026
Gufic Biosciences Limited will host an Earnings Conference Call on June 1, 2026, at 04:30 PM IST. Company officials will discuss business prospects and financial performance, followed by a Q&A session. Dial-in details and a pre-registration link are provided.
Read the summary - Medium impact
Gufic Biosciences Invests USD 50,000 in Selvax Pty Ltd for Cancer Treatment
Gufic Biosciences invested USD 50,000 in Selvax Pty Ltd by acquiring 3,78,350 shares. Selvax is an Australian biotech firm developing novel immunology-based treatments for solid tumors. This strategic investment diversifies Gufic Biosciences into healthcare and biotechnology.
Read the summary - Low impact
Gufic Biosciences Announces Special Window for Share Transfer & Dematerialization
Gufic Biosciences opens a special window for physical share transfer and dematerialization from February 5, 2026, to February 4, 2027. This allows shareholders who sold securities before April 1, 2019, to lodge transfer deeds. Transferred securities will be locked in for one year.
Read the summary - Low impact
Gufic Biosciences Files SEBI Compliance Certificate for Q4 FY26
Gufic Biosciences Limited submitted a compliance certificate for the quarter ended March 31, 2026, as per SEBI regulations. The RTA confirmed processing of dematerialized securities and no shareholder requests were received during the period.
Read the summary - Low impact
Gufic Biosciences: Tax Demand Reduced to ₹11.76 Lakhs, Penalty ₹23.52 Lakhs
Gufic Biosciences' tax demand for AY 2023-24 reduced from ₹11.89 Crore to ₹11.76 Lakhs. A penalty of ₹23.52 Lakhs was levied. The company is evaluating the order and plans to appeal, expecting a favorable outcome.
Read the summary - Low impact
Gufic Biosciences: Trading Window Closed for Audited Financial Results
Gufic Biosciences Limited will close its trading window from April 1, 2026, until 48 hours after the announcement of audited financial results for the quarter and financial year ended March 31, 2026. The board meeting date for results approval will be intimated later.
Read the summary - Low impact
Gufic Biosciences Pays ₹1.72 Lakh Penalty to BSE for Director Appointment Non-Compliance
Gufic Biosciences paid a penalty of ₹1,72,000 to BSE on March 13, 2026. This is for alleged non-compliance regarding the appointment of an independent director over 75 years old without shareholder approval. The company had previously paid ₹8,000 to BSE and NSE for similar non-compliance in Q2 FY25.
Read the summary - Low impact
Gufic Biosciences: Special Window for Share Transfer & Dematerialization
Gufic Biosciences announces a special window for re-lodging transfer deeds and dematerializing physical shares. The window is open from February 05, 2026, to February 04, 2027. This applies to transfers executed before April 01, 2019. Transferred shares will have a one-year lock-in period.
Read the summary - Low impact
Gufic Biosciences: Transcript of Earnings Conference Call Released
Gufic Biosciences Limited has released the written transcript of its earnings conference call held on February 16, 2026. The transcript is available on the company's website.
Read the summary - Low impact
Gufic Biosciences: Audio Recording of Earnings Conference Call Uploaded
Gufic Biosciences has uploaded the audio recording of their earnings conference call held on February 16, 2026. A written transcript will be provided soon. The recording is available on the company's website.
Read the summary - Low impact
Gufic Biosciences Q3 FY26 Results Announced
Gufic Biosciences Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved the results on February 13, 2026. Detailed results are available on the company and stock exchange websites.
Read the summary - Medium impact
Gufic Biosciences Approves Q3 FY26 Results and Invests in Selvax Pty Ltd
Gufic Biosciences Limited approved its Q3 FY26 unaudited financial results. The company also approved a further investment of up to USD 50,000 in Selvax Pty Ltd, an Australian biotech firm. This strategic acquisition aims to diversify into oncology treatments and is expected to complete within four months.
Read the summary - Medium impact
Gufic Biosciences Presents Q3 FY26 Investor Presentation
Gufic Biosciences released its Q3 FY26 investor presentation. The company is progressing with its new Indore facility and expanding its product portfolio in critical care, women's health, and aesthetics. International business is shifting towards IP-owned markets. Q3 FY26 revenue was ₹231.1 crore, with PAT at ₹15.6 crore.
Read the summary - Medium impact
Gufic Biosciences Approves Q3 FY26 Unaudited Results, Invests in Selvax
Gufic Biosciences approved Q3 FY26 unaudited financial results. The company will invest up to USD 50,000 in Selvax Pty Ltd. for 3,78,350 shares at AUD 0.20 each. This strategic move diversifies Gufic into biotechnology for cancer treatments. The acquisition is expected within 4 months.
Read the summary - Medium impact
Gufic Biosciences Approves Q3 FY26 Results & Invests USD 50,000 in Selvax Pty Ltd.
Gufic Biosciences approved Q3 FY26 unaudited financial results. The company also approved an investment of up to USD 50,000 in Selvax Pty Ltd. for 3,78,350 shares. Selvax is an Australian biotech firm developing cancer treatments. The acquisition is expected to complete within four months.
Read the summary - Low impact
Gufic Biosciences to Host Earnings Conference Call on Feb 16, 2026
Gufic Biosciences Limited will host an Earnings Conference Call on February 16, 2026, at 4:30 PM IST. Company officials will discuss financial performance and business prospects, followed by a Q&A session.
Read the summary - Low impact
Gufic Biosciences to Meet Investors at Manthan Conference on Feb 9
Gufic Biosciences Limited will attend the Manthan – Systematix India Annual Flagship Conference on February 09, 2026, in Mumbai. The company will hold one-on-one or group meetings with analysts and institutional investors. Discussions will be limited to publicly disclosed information.
Read the summary - Medium impact
Gufic Biosciences Receives ₹4.33 Crore Income Tax Demand for AY 2024-25
Gufic Biosciences Limited received an Income Tax demand of ₹4.33 crore for AY 2024-25 due to disallowed expenditure. The company plans to appeal the order before the Commissioner of Income Tax (Appeal) and is optimistic about a favorable outcome.
Read the summary - Low impact
Gufic Biosciences Files SEBI Compliance Certificate for Q3 FY26
Gufic Biosciences Limited submitted a SEBI compliance certificate for Q3 FY26. The company's RTA, MUFG Intime India, confirmed processing of dematerialized securities and no shareholder requests during the quarter ended December 31, 2025.
Read the summary - Low impact
Gufic Biosciences: Trading Window Closed Jan 1, 2026 for Q3 FY26 Results
Gufic Biosciences will close its trading window from January 1, 2026. This is in compliance with SEBI regulations and will remain closed until 48 hours after the declaration of Q3 FY26 unaudited financial results. The board meeting date for approving these results will be announced later.
Read the summary - Low impact
Gufic Biosciences faces ₹15.64 lakh penalty; plans appeal.
Gufic Biosciences Limited received an order imposing a total penalty of ₹15,64,052 for excess Input Tax Credit and short payment of tax liability for FY19-FY23. The company plans to appeal the order, stating it will not materially impact operations.
Read the summary - Low impact
Gufic Biosciences Assigned ESG Rating of 68.2/100 by SES ESG Research
Gufic Biosciences Limited received an ESG rating of 68.2/100 (Category: Medium) for FY 2024-25 from SES ESG Research. SES, a SEBI registered provider, assigned the rating independently based on public information. The company received the report on December 09, 2025.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio